GlaxoSmithKline Intellectual Property Development Limited
发明人:
Grant, Steven,Akinseye, Chika,Bhinder, Tejinder,Hook, Laura,Lewis, Alan Peter,Orecchia, Martin
申请号：
AU2018273174
公开号：
AU2018273174A1
申请日:
2018.05.24
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
The present disclosure relates to antigen binding compositions, including antibodies, for treating interleukin 5 (IL-5) mediated diseases, and related methods. IL-5 is a secreted protein. IL- 5 plays a role in a number of different diseases such as asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, sub-eosinophilic asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, nasal polyposis, bullous pemphigoid, eosinophilic esophagitis, atopic dermatitis, moderate atopic dermatitis and severe atopic dermatitis. The disclosed compositions are suitable for treating these serious IL-5 mediated diseases.
